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KAJIAN KEKERAPAN POLIMORFISME GEN RESEPTOR BETA-2 (β2AR) DI 
KALANGAN MASYARAKAT MELAYU SERTA KESAN PEWARISAN GEN 
TERSEBUT KE ATAS SATU MODEL MENGUKUR FUNGSI SALUR DARAH 
BESAR 
 
ABSTRAK 
 
 
Disfungsi endotelium mendahului proses aterosklerosis. Pengukuran fungsi endotelium 
akan membolehkan pengesanan awal ke atas aterosklerosis dan membantu strategi 
rawatan. Baru-baru ini, “pulse wave analysis” (PWA) yang digandingkan dengan 
provokasi farmakologi menunjukkan potensi sebagai metodologi pengukuran 
endotelium secara tidak invasif. Provokasi farmakologi menggunakan “sublingual 
Glyceryl Trinitrate” (GTN) sebagai vasodilator yang tidak bergantung kepada 
endotelium manakala “inhaled salbutamol” sebagai vasodilator yang bergantung kepada 
endotelium. Tindakbalas terhadap salbutamol, iaitu agonis beta-2 berkemungkinan 
dipengaruhi oleh faktor polimorfisme genetik reseptor beta-2 adrenergic (β2AR). 
Polimorfisme β2AR turut dikaitkan dengan patogenesis pelbagai penyakit, termasuk 
perbezaan tindakbalas pesakit terhadap rawatan yang dipengaruhi β2AR. 
 Objektif tesis ini adalah untuk menentukan kekerapan polimorfisme genetik 
β2AR di kalangan masyarakat dan juga untuk menentukan sama ada kesan pewarisan 
polimorfisme tersebut mempengaruhi model yang digunakan untuk mengukur fungsi 
endotelium salur darah besar menggunakan PWA. 
 Proses genotip dibuat untuk mengesan 5 “single nucleotide polymorphisms” 
(SNP) yang penting dari segi fungsi di kalangan 388 subjek Melayu yang sihat. 
Kesemua SNP dikesan sekaligus menggunakan metodologi “allele-specific multiplex 
PCR”. Dari kalangan subjek tersebut, seramai 298 menjalani kajian klinikal melibatkan 
pengukuran fungsi endotelium salur darah besar. Pengukuran garis dasar “augmentation 
index” (AIx) dan “carotid-femoral pulse wave velocity” (PWV) dibuat menggunakan 
 xvi
alat SphygmoCor yang tidak invasif. Subjek kemudian diberi GTN diikuti dengan 
rakaman bacaan AIx dan PWV. Selepas tempoh penyucian, 400 µg salbutamol diberi 
dan diikuti rakaman bacaan AIx dan PWV. Perubahan maksima AIx dan PWV selepas 
setiap provokasi farmakologi diambil sebagai bacaan akhir. 
 Frekuensi allel varian Gly16, Glu27, Ile164, -20C dan -47C masing-masing 
adalah 47%, 6.8%, 0%, 30% dan 9.3%. Dari segi frekuensi genotip, genotip paling 
kerap bagi kodon 16 dan 27 adalah masing-masing Arg/Gly dan Gln/Gln dengan 
frekuensi 81.4% dan 87.1%; bagi nucleotide -20 dan -47 adalah TT dengan frekuensi 
50% dan 82.2% masing-masing; manakala 100% genotip bagi kodon 164 adalah 
Thr/Thr. Tiada perbezaan yang signifikan pada keputusan AIx selepas GTN dan 
salbutamol bagi setiap kumpulan. Begitu juga, tiada perbezaan signifikan pada 
keputusan PWV selepas GTN dan salbutamol bagi setiap kumpulan. 
 Sebagai rumusan, kekerapan polimorfisme genetik β2AR di kalangan 
masyarakat Melayu menepati kekerapan di kalangan masyarakat Asia. Model yang 
digunakan untuk mengukur fungsi endotelium salur darah besar juga tidak dipengaruhi 
oleh polimorfisme β2AR. 
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 PREVALENCE OF BETA- 2 ADRENERGIC (β2AR) RECEPTOR 
POLYMORPHISMS IN MALAY POPULATION AND RELATIONSHIP OF 
THESE POLYMORPHISMS TO A MODEL ASSESSING MACROVASCULAR 
ENDOTHELIAL FUNCTION 
 
 
ABSTRACT 
 
 
Endothelial dysfunction has been shown to precede atherosclerosis. The assessment of 
endothelial function allows early detection of atherosclerosis and may help in 
preventive strategies. Recently, pulse wave analysis (PWA) combined with 
pharmacological challenges has been shown to be a promising non invasive method of 
assessing endothelium function. The pharmacological challenges involve 
administrations of sublingual glyceryl trinitrate (GTN) as an endothelium-independent 
vasodilator and inhaled salbutamol as an endothelium dependent vasodilator.  The 
response to salbutamol, a β2-agonist may be affected by genetic polymorphisms of Beta-
2 adrenergic receptor (β2AR). Beta-2 adrenergic receptor polymorphisms have been 
implicated in the pathogenesis of many diseases as well as inter individual differences 
in patients’ response to treatment mediated by β2AR.  
 The objectives of this thesis were to determine the prevalence of β2AR 
polymorphisms in our population and to determine if these polymorphisms influence the 
model used to assess macrovascular endothelial function using PWA. 
 Genotyping was done to detect 5 functionally important single nucleotide 
polymorphisms (SNPs) of β2AR in 388 healthy Malay subjects. All SNPs were 
simultaneously detected using the published method allele specific nested multiplex 
polymerase chain reaction (PCR). Out of this, 298 subjects proceeded with clinical 
measurement of macrovascular endothelial function. Augmentation index (AIx) and 
carotid-femoral pulse wave velocity (PWV) recordings were taken at baseline, done 
non-invasively using SphygmoCor. Subjects were then administered with 500 µg of 
 xviii
sublingual GTN followed by AIx  and PWV recordings. After a wash-out period, 400 
µg of inhaled salbutamol was given followed by AIx and PWV recordings. The 
maximum changes in AIx and PWV after each pharmacological challenge were taken as 
final measurements. 
 The frequencies of variant alleles Gly16, Glu27, Ile164, -20C and -47C were 
47%, 6.8%, 0%, 30% and 9.3% respectively. In term of genotype frequencies, for 
codons 16 and 27 the most common genotypes were Arg/Gly and Gln/Gln with 
frequencies 81.4% and 87.1% respectively; for nucleotides -20 and -47 were TT with 
frequencies 50% and 82.2% respectively; whereas at codon 164, 100% of the genotype 
was Thr/Thr. No significant differences were noted in AIx after GTN and salbutamol in 
all groups. Similarly, no significant differences were noted in PWV after GTN and 
salbutamol in all groups. 
 In conclusion the prevalence of β2AR polymorphisms in Malays in our 
population correspond to that reported in other Asian populations. Model used to assess 
macrovascular endothelial function using PWA was not influenced by β2AR 
polymorphisms. 
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CHAPTER 1 
INTRODUCTION 
 
 
  
1.1 Endothelial function and cardiovascular health 
 
The history of endothelial function started back in the days of William Harvey 
where it has already been accepted that blood is fluid in living and healthy vessels but 
coagulates in dead ones. Later, the discovery by Furchgott and Zawadzki (1980) described 
the role of endothelium in vasodilatation, whereby acetylcholine was shown to require an 
intact endothelium in order to produce vasodilatation. This landmark study lead to the 
current understanding that endothelium plays an essential role in cardiovascular 
homeostasis.  
 
The functions of endothelium include regulating the vascular tone, maintaining the 
fluidity and coagulation of blood and producing mediators of inflammatory processes. The 
vascular tone is controlled by balancing the production of vasodilators and vasoconstrictors. 
Fluidity and coagulation of the blood is controlled by endothelium through the production 
of factors that regulate platelet activity, clotting cascade and the fibrinolytic system. 
Additionally, endothelium also produces cytokines and adhesion molecules which are 
responsible for inflammatory processes (Endemann and Schiffrin, 2004). 
 
Endothelial dysfunction is associated with most forms of cardiovascular diseases as 
shall be discussed in detail below. Atherosclerosis, the earlier manifestations of 
cardiovascular disease has been closely linked to endothelial dysfunction. Over the last 30 
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years, since the discovery by Furchgott and Zawadzki (1980), it has increasingly become 
clear that the initiation and progression of cardiovascular disease largely depends upon the 
changes in the vascular homeostasis. This important implication leads to an increasing 
number of research geared towards understanding the functions and dysfunctions of 
endothelium, in the hope that cardiovascular disease may be prevented at the earlier stage 
of endothelial dysfunction. 
 
In Malaysia, data from the Ministry of Health showed that cardiovascular disease 
had been the principal cause of death in the government hospitals, accounting for 23 – 36% 
of deaths from 1994 to 2001 (Zambahari, 2004). The National Health and Morbidity 
Survey (1996) also showed that atherosclerotic risk factors are common among Malaysians 
with 61% having one or two risk factors (Lim et al., 2000). Taking preventive measures at 
an earlier stage of endothelial dysfunction would definitely help in the preventive strategies 
against cardiovascular disease. The tool to assess endothelial function should ideally be 
simple, non-invasive and largely applicable in large population studies. To date however, 
the consensus on the most ideal tool has not been reached.  
 
1.2 Anatomy and physiology of endothelium 
 
Endothelium is a single cell layer in the tunica intima, the innermost lining of the 
blood vessel wall. It comes from the words endo meaning within and –thelium meaning 
covering. Other than the arteries and veins, it also lines other cavities including the heart 
and lymphatic vessels (Tortora and Grabowski, 2003). 
 
 2
Physiologically, other than acting as a barrier between the circulating blood and 
vessel wall, endothelium plays a crucial role in maintaining vascular homeostasis. It senses 
either mechanical stimuli such as pressure and shear stress, or biochemical stimuli. In 
response to these stimuli, it releases a number of active substances in the form of 
vasodilators and vasoconstrictors. These also act as antiproliferative and proliferative 
substances, antithrombotic and prothombotic agents, as well as angiogenesis, permeability 
and inflammatory markers (Verma and Anderson, 2002). 
 
Vasodilators released by the endothelium include nitric oxide (NO), originally 
termed endothelium derived relaxing factor (EDRF). Other vasodilators are prostacyclin, 
bradykinin and endothelium-derived hyperpolarising factor. They act synergistically to 
overcome the effect of vasoconstrictors, proliferative and prothrombic agents. For instance, 
both prostacyclin and NO inhibit platelet aggregation. Bradykinin stimulates the release of 
these vasodilators to contribute more in inhibiting platelet aggregation. In addition, it also 
stimulates the production of tissue plasminogen activator (t-PA), resulting in fibrinolysis 
(Drexler, 1998, Luscher and Barton, 1997). Among the vasoconstrictors released by the 
endothelium are endothelin-1, angiotensin II, thromboxane A2 and reactive O2 species 
(ROS). These vasoconstrictors are also responsible for proliferation of smooth muscle cells 
and thus contribute to plaque formation. In order to maintain the vascular homeostasis, 
these endothelium-derived vasodilators and vasoconstrictors are kept in balance. Any 
injurious stimulus that disrupts the balance will lead to a condition known as “endothelial 
dysfunction”.  
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1.3 Endothelial dysfunction and its pathophysiology 
  
 Endothelial dysfunction is characterized by a reduction in the bioavailability of 
vasodilators, particularly NO, and a reciprocal increase in the vasoconstrictors. This leads 
to a state of reduced vasodilatation and an increase in vasoconstriction, as well as 
inflammatory, proliferative and procoagulatory state.  
 
 The association of endothelial dysfunction and the risk factors for atherosclerosis 
and cardiovascular disease is well-established. However, the mechanism leading to the 
lesion is complex and not well-defined. A few mechanisms leading to the dysfunction of 
the endothelium have been proposed, as discussed below. It involves the interplay of many 
factors, the most important being NO. 
 
1.3.1 Nitic oxide (NO) 
  
 Nitric oxide is one of the most potent vasodilators released by the endothelium. As 
well as acting as a vasodilating agent, it also inhibits inflammation and platelet aggregation. 
In the endothelial cells, NO is formed from its precursor L-Arginine by the action of the 
enzyme endothelial NO synthase (eNOS), with the presence of cofactors such as 
tetrahydrobiopterin (Werner et al., 2003). Nitric oxide then diffuses to the vascular smooth 
muscle cell and activates guanylate-cyclase, leading to c-GMP mediated vasodilatation. 
This is the result of normal physiological response by eNOS to stimuli such as shear stress.  
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 In endothelial dysfunction, NO has been reported to be reduced due to reduced 
activity of eNOS. One proposed mechanism is ‘uncoupling of eNOS’, whereby there is a 
switch in the normal function of eNOS from generating NO to instead generating reactive 
oxygen species (ROS) (Endemann and Schiffrin, 2004). The resulting ROS production 
leads to the generation of hydrogen peroxide or superoxide formation (Estevez and Jordan, 
2002). Moreover, ROS further reduces NO bioavailability and thus promotes more cellular 
damage (Bonetti et al., 2003b).  
 
1.3.2 Asymmetric Dimethylarginine (ADMA) 
  
 NG,NG-dimethylarginine or asymmetric dimethylarginine (ADMA) is the product of 
protein turnover in the cytoplasm and eliminated via the kidney. It is also the endogenous 
competitive inhibitor of eNOS. In a group of patients with chronic renal diseases, inhibition 
of eNOS was shown to be correlated with plasma ADMA levels (Xiao et al., 2001). In 
subjects with hypercholesterolaemia, high ADMA levels were shown to be inversely 
correlated with endothelial-dependent vasodilatation, which is a form of assessing 
endothelial function (Boger et al., 1998). Moreover, in response to shear stress, ADMA 
generation was also shown to be increased (Osanai et al., 2003). Thus, ADMA generation 
is another proposed mechanism in the pathophysiology of endothelial dysfunction. 
 
1.3.3 Oxidative excess 
  
 Many of the risk factors of atherosclerosis including hyperlipidaemia, hypertension, 
smoking and diabetes are found to be associated with oxidative stress or excess. Oxidative 
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excess which has been shown to diminish NO, also correlates with the impairment of 
endothelium-dependent vasodilatation and cardiovascular events (Heitzer et al., 2001). 
Findings from animal and human studies showed that treatment with antioxidants may 
improve endothelial function (Cross et al., 2003, Vaziri et al., 2002). The mechanism of 
oxidative excess includes the generation of ROS as mentioned above. 
 
1.3.4 Others 
 
 Other factors which have also been implicated in the pathophysiology of endothelial 
dysfunction include excess of angiotensin II, hyperhomocysteinaemia and insulin 
resistance.  
 
 Angiotensin II infusion in animals has been shown to induce endothelial 
dysfunction and vascular inflammation (Diep et al., 2002a, Diep et al., 2002b). Similarly in 
humans, angiotensin II infusion in healthy volunteers has been shown to be associated with 
arterial stiffness (Rehman et al., 2001). Treatment of hypertensive patients with angiotensin 
converting enzyme (ACE) inhibitors or angiotensin receptor blockers had an additional 
effect of improving endothelial function in contrast to treatment with β-blockers which had 
no similar effect on endothelial function (Schiffrin et al., 2002, Schiffrin, 1996). The 
proposed mechanism includes the increase in nicotinamide adenine dinucleotide phosphate 
oxidase (NADPH) activity caused by angiotensin II. This leads to an increase in the 
production of ROS and further inactivation of NO (Griendling et al., 2000).  
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 As for hyperhomocysteinaemia, it has been evidenced in both animals and human 
studies that hyperhomocysteinaemia is linked to endothelial dysfunction (Virdis et al., 
2003, Virdis et al., 2001). Some studies have shown that treatment with folic acid which 
reduces homocysteine levels improved endothelial function (Bennett-Richards et al., 2002, 
Title et al., 2000).  
 
 An emerging aspect in the study of endothelial function is the role of endothelial 
progenitor cells (EPC). Endothelial progenitor cells are the primitive bone marrow cells 
which have the ability to mature as endothelial cells as well as having the ability to repair 
endothelial lesions (Szmitko et al., 2003). It has been shown that the levels of circulating 
EPC inversely correlate with endothelial dysfunction (Hill et al., 2003). Thus, deficiency of 
EPC may be another possible mechanism for endothelial dysfunction.  
 
1.4 Clinical implications of endothelial dysfunction 
  
 As mentioned earlier, endothelial dysfunction has been implicated in the 
pathogenesis and clinical courses of many cardiovascular related diseases. The study of 
endothelial function in humans was first described in patients with coronary artery disease, 
whereby impaired endothelium-dependent vasodilatation was detected in the presence of 
atherosclerosis (Ludmer et al., 1986).  
 
 Many studies have shown that the coronary risk factors which predispose to the 
development of atherosclerosis are actually associated with endothelial dysfunction. It was 
first being associated with hypertension, when impaired vasodilatation was described in 
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hypertensive patients (Panza et al., 1990). Thereafter, endothelial dysfunction was also 
being described with other coronary risk factors such as smoking, diabetes mellitus, chronic 
renal failure and hypercholesterolaemia (Covic et al., 2004, Endemann and Schiffrin, 2004, 
Engler et al., 2003, Vita et al., 1990). More importantly, as well as in patients with 
established diseases, endothelial dysfunction has also been described in a group of children 
and adults who were at risk of atherosclerosis, but had not developed any clinical 
manifestations or any plaque formation in the vessel wall (Celermajer et al., 1992). This 
leads to an important postulation that endothelial dysfunction precedes atherosclerosis. 
Additionally, in patients with established coronary artery disease, the presence of 
endothelial dysfunction has been shown to be associated with future events (Schachinger et 
al., 2000, Suwaidi et al., 2000). Thus, detection of endothelial dysfunction may serve as a 
preventive, monitoring as well as a prognostic tool as far as cardiovascular disease is 
concerned.  
 
 Based on the association between endothelial dysfunction and cardiovascular 
related diseases, it has been postulated that early intervention may reverse endothelial 
dysfunction and in turn reduce the risk of cardiovascular disease. To date, no gold standard 
treatment has yet been available for endothelial dysfunction. However, several 
pharmacological and non-pharmacological measures have been shown to improve 
endothelial function as well as cardiac events.  
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1.4.1 Non-pharmacological interventions 
  
 Exercise is a lifestyle modification that has been proven to improve cardiovascular 
function and reduce cardiac events. An increase in NO bioavailability especially in the 
coronary vessels has been associated with exercise (Gokce et al., 2002, Gielen et al., 2001, 
Taddei et al., 2000). Not surprisingly, regular exercise has been shown to improve 
endothelium-dependent vasodilatation in young men of average fitness (Clarkson et al., 
1999) as well as in patients with established coronary artery disease (Bonetti et al., 2003a, 
Hambrecht et al., 2003, Hambrecht et al., 2000).  
 
 Dietary modifications i.e. low in fat and high in fruits and vegetables as 
recommended by the American Heart Association (2000) has been proven to reduce 
cardiovascular risk (Krauss et al., 2000). These flavonoids-rich foods may improve 
endothelial function (Widlansky et al., 2003), as evidenced by a reversal in endothelial 
dysfunction after intake of tea (Duffy et al., 2001), red wine (Agewall et al., 2000) and dark 
chocolate (Vlachopoulos et al., 2005). On the other hand, consumption of high-fat meals in 
a group of healthy volunteers was shown to worsen endothelial function (Vogel et al., 
1997).  
 
 Other lifestyle modifications which improve cardiovascular risk were also shown to 
improve endothelial function, such as weight loss, blood pressure reduction and smoking 
cessation (Ziccardi et al., 2002, Modena et al., 2002, Celermajer et al., 1993). 
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1.4.2 Pharmacological interventions 
  
 A reduction in plasma low-density lipoprotein (LDL) has been shown to improve 
endothelial function. These include non-pharmacological measures like low cholesterol diet 
as well as treatment with bile acid resins (Widlansky et al., 2003). Treatment with 3-
hydroxy-3-methyl-glutaryl-Co-A (HMG Co-A) reductase inhibitor or statins has been 
shown to reduce cardiovascular events, partly by improving the endothelial function 
(Wolfrum et al., 2003). Treatments with statins have consistently been shown to reverse 
endothelial dysfunction (Masumoto et al., 2001, Perticone et al., 2000, Anderson et al., 
1995a). While the effect of lowering LDL-cholesterol may be the predominant mechanism 
for the improvement in endothelial function (Tamai et al., 1997), its cholesterol-
independent (pleiotropic) effect has increasingly been shown to be partly responsible 
(Takemoto and Liao, 2001, Masumoto et al., 2001, O'Driscoll et al., 1997). 
 
 Angiotensin II has been implicated in the pathophysiology of endothelial 
dysfunction as mentioned before. Patients treated with angiotensin converting enzyme 
(ACE) inhibitors have been shown to improve endothelial function, independent of blood 
pressure reduction (Schiffrin et al., 2002, Anderson et al., 2000, Prasad et al., 2000, 
Mancini et al., 1996, Schiffrin, 1996). The benefit is further supported by similar findings 
in treatment with angiotensin receptor blockers (ARB) (Schiffrin et al., 2002, Wassmann et 
al., 2002, Hornig et al., 2001, Schiffrin et al., 2000). The currently ongoing large scale 
clinical trial, The Ongoing Telmisartan Alone and in combination with Ramipril Global 
Endpoint Trial (ONTARGET) is expected to provide the ultimate evidence that treatment 
with ARB and / or ACE inhibitors reverse endothelial dysfunction and whether that reduces 
 10
cardiovascular events in high risk patients (Teo et al., 2004). This trial is expected to be 
completed in 2008. 
 
 There are a number of potential treatments undergoing studies which may be 
promising, some of which have been shown to improve endothelial function. The 
administration of L-Arginine (precursor of NO) in healthy volunteers has been shown to 
improve endothelial function in some studies involving healthy volunteers as well as 
patients with coronary artery disease (Bode-Boger et al., 2003, Lerman et al., 1998, Adams 
et al., 1997). Other potential pharmacological interventions being studied include 
tetrahydrobiopterin (co-factor for eNOS), protein-kinase c and cyclooxygenase inhibitions 
(Chenevard et al., 2003, Beckman et al., 2002, Heitzer et al., 2000).  
 
1.5 Assessment of endothelial function 
 
Early detection of endothelial dysfunction before any clinical manifestations 
develop will help in the preventive measures and reduce possible complications. It can also 
help in making the prognosis, predict the possible outcome and monitor the efficacy of 
treatments given. An ideal assessment tool will have to be safe, non-invasive, simple, 
reproducible, practical, reliable and cost-effective. To date, no particular test has yet to 
fulfill all the requirements, each having its own advantages as well as disadvantages. 
 
Over the years, endothelial function is assessed via various methods. The main 
assessment methods would either be testing the endothelial vasomotor function or 
measuring the circulating biomarkers of endothelial dysfunction in the blood. 
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1.5.1 Endothelial-dependent vasomotor function assessment 
 
The endothelial vasomotor function can readily be assessed whether centrally in the 
coronary artery or in the peripheral circulation. The test of endothelial vasomotor function 
is based on the principle that introduction of certain stimuli trigger the release of NO from 
the endothelium causing endothelium-dependent vasodilatation (Lerman and Zeiher, 2005). 
Endothelium-dependent vasodilatation involves the introduction of a stimulus, either 
physiological or pharmacological; resulting in an increase in the production of 
endothelium-derived NO and other vasoactive substances. Common stimuli used include 
increase shear stress induced by reactive hyperaemia or administration of receptor-
dependent agonists such as acetylcholine, bradykinin, β2-receptor agonists and substance P 
(Farouque and Meredith, 2001). The parameter used is endothelium-dependent 
vasodilatation, whereby a resultant normal dilatation indicates a healthy endothelium 
whereas a reduced dilatation indicates endothelial dysfunction. It is often performed in 
comparison with vascular responses to endothelium-independent vasodilators e.g. sodium 
nitroprusside and glyceryl trinitrate (GTN), which acts as control.  
 
In different vascular beds, different types of assessment tools are used. Thus, the 
assessment tools and methods for micro and macrovascular are different. Macrovascular or 
conduit vessels are those measuring above 100 µm in internal diameters. These include all 
the large vessels for example coronary artery in the centre and brachial and femoral arteries 
in the periphery.  
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1.5.1.1 Assessment in coronary circulation 
 
Earlier studies involved the assessment of endothelial function in the coronary 
vessels. The methods used in the coronary circulation are coronary angiography and 
intracoronary Doppler. These measurements provide the direct calculation of coronary 
blood flow (in macrovascular) and coronary vascular resistance (in microvascular) 
respectively (Schachinger et al., 2000, Suwaidi et al., 2000).  
 
Ludmer et al. (1986) were the first to describe the assessment of endothelial 
function in humans, whereby angiography was used. They demonstrated the effect of 
acetylcholine on endothelium in humans by assessing the epicardial coronary vessels using 
the method called quantitative coronary angiography (QCA). It involves an invasive 
intracoronary infusion of acetylcholine and GTN assessed by coronary angiography. 
Acetylcholine is a muscarinic endothelium-dependent vasodilator which stimulates the 
endothelial cells to release vasoactive agents including NO (Newby et al., 1997). A healthy 
endothelium is indicated by a mild vasodilatation, whereas endothelial dysfunction results 
in a paradoxical vasoconstriction. Glyceryl trinitrate is an endothelium-independent 
vasodilator and thus all patients were expected to respond with vasodilatation, indicating 
the integrity of smooth muscle cells.  
 
In the coronary microvasculature, intracoronary Doppler measurement involves the 
placement of Doppler wire into the coronary artery (mid-left anterior descending artery). 
Blood flow velocity is then measured after the infusions of endothelium-dependent (e.g. 
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acetylcholine) and endothelium-independent (e.g. papaverine and adenosine) vasodilators 
respectively (Treasure et al., 1993).  
 
Other than the pharmacological stimuli above, the physiological stimuli are also 
used such as cold pressor test and dynamic exercise. Cold pressor test is based on 
sympathetic stimulation which is achieved after immersing a patient’s hand in ice-cold 
water for 90 seconds. This is followed by measurements of blood flow velocity and 
angiography (Nabel et al., 1988). Dynamic exercise test is performed using ergometer, with 
continuous haemodynamic monitoring and repeated angiography before, during and after 
exercise, as well as after GTN infusion (Deanfield et al., 2005). 
 
Although the assessment in the coronary vascular bed may provide the direct 
measurement of coronary endothelial function which is also the target of atherosclerosis, its 
invasive nature is the main limitation. Moreover, coronary angiography and intracoronary 
Doppler are operator dependent. Thus, all these factors confine the assessment to only 
patients scheduled for certain interventional procedures and are not suitable to be used in 
large scale studies. 
 
1.5.1.2 Assessment in peripheral circulation 
  
 The assessment of endothelial function in the peripheral circulation is based on the 
principle that endothelial function is a systemic disorder and thus can be measured in any 
vascular beds. This is evidenced by findings that impaired vascular responses in the 
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coronary circulation have also been confirmed with the same impaired responses in other 
vascular beds in the peripheral circulations (Takase et al., 1998, Anderson et al., 1995b). 
 
 Using the same endothelium-dependent vasodilatation principle, the stimuli in the 
peripheral circulation include intra-arterial local infusion of vasodilators (e.g. 
acetylcholine) or the less invasive approach of shear stress induced by reactive hyperaemia. 
Vasodilators are also administered systemically in a non-invasive manner; e.g sublingual 
GTN or inhaled salbutamol. 
 
 Flow mediated dilatation (FMD) is a popular and widely used assessment method of 
macrovascular function in the peripheral circulation. It involves physiological stimulus of 
shear stress for the release of NO and other vasoactive substances by the endothelium. 
Shear stress is induced by the introduction of reactive hyperaemia which represents an 
ischaemia in the distal tissue. In response to the short ischaemia, there is a transient 
increase in the blood flow with a resultant shear stress. The change in the diameter in the 
conduit artery (e.g. brachial artery) is measured using a high resolution 2D ultrasound 
system. Flow mediated dilatation is defined as the change in the artery diameter following 
the stimulus, expressed as percentage of baseline diameter. In most studies the 
endothelium-independent vasodilator given is sublingual GTN (Deanfield et al., 2005, 
Corretti et al., 2002, Celermajer et al., 1992). Given the non-invasive nature of the 
measurement together with its relative simplicity, this method has been widely used in 
relatively large scale trials. It is however highly operator dependent as well as involving 
some technical variances between centres which may limit the interpretation of the study 
results. 
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 Another method for studying macrovasculature is the forearm perfusion technique 
by measuring the forearm blood flow (FBF). It involves an invasive placement of a catheter 
in the brachial artery for direct infusion of pharmacological agents. The measurement of 
blood flow is then performed non-invasively using strain gauge plethysmography or venous 
occlusion plethysmography, whereby the variations in the limb volume placed in the 
mercury strain gauge are reflected in the change of the circumference of the strain gauge 
and recorded by the plethysmograph. This technique is based on the principle that 
obstruction in the venous outflow is reflected in the increase in the limb volume, and it is 
directly proportional to the rate of arterial inflow (Deanfield et al., 2005). The downside of 
this technique is its invasive nature which may also limit the application. 
 
 Recently, a non-invasive method based on the technique of pulse wave analysis 
(PWA) has been implemented in the assessment of macrovascular endothelial function. 
Pulse wave analysis is a non-invasive technique to assess arterial stiffness via the 
measurement of augmentation index (AIx). The method of applanation tonometry is used, 
involving the placement of a tonometer (pen-like probe) over the maximal and superficial 
arterial pulsation under study (e.g. radial artery), from which a corresponding central aortic 
waveform is generated by using a validated transfer function. Augmentation index is the 
difference between the first and second systolic peaks of the central waveform, expressed 
as a percentage of pulse pressure. In the study of endothelial function, pharmacological 
challenge in the form of β2-receptor agonist (e.g. salbutamol) is administered systemically 
via inhalation technique (Hayward et al., 2002, Wilkinson et al., 2002a). The changes in 
AIx elicited after the administration of this endothelium dependent vasodilator can be used 
as a tool to measure endothelial function. The endothelium-independent vasodilator 
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administered which acts as a control is sublingual GTN. It has been shown that β2-receptor 
agonist induced, but not GTN induced changes could be inhibited by the NG-monomethyl-
L-arginine (L-NMMA), a specific inhibitor of eNOS. This indicates that the effect of β2-
receptor agonist is in part, mediated through the endothelial NO release, and thus pulse 
waveform analysis can be applied as a non-invasive and simple method for assessing 
endothelial function (Wilkinson et al., 2002a).  A recent study compared FMD, PWA and 
pulse contour analysis as methods for assessing endothelial function in adults and children 
(Donald et al., 2006). While FMD was still concluded as the non-invasive technique of 
choice followed by PWA, the role of PWA is promising. There have been increasingly 
more studies on endothelial function using this method, and further studies are needed to 
look into the reproducibility and possible factors that may affect the measurement. 
 
 In the microvasculature, a relatively new and non-invasive method of assessment is 
laser Doppler flowmetry (LDF). It has been implemented to evaluate the endothelial 
function in the skin microvasculature using the technique of postocclusive hyperaemia, 
local thermal hyperaemia or acetylcholine iontophoresis (Cracowski et al., 2006). However, 
recent findings suggested that the mechanism of postocclusive hyperaemia in this 
microvasculature is not primarily NO mediated and thus does not represent a specific 
marker for endothelial function but rather a form of assessing overall microvascular 
function (Wong et al., 2003). 
 
 Pulse wave amplitude in the microvasculature is assessed by measuring the digital 
pulse volume in the finger using pulse contour analysis. The mechanism is similar to the 
application of PWA in assessing the macrovascular endothelial function as explained 
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above. Beta 2-receptor stimulation in the microvasculature was also shown to result in 
characteristic changes in digital pulse volume, and thus the agonist is also used to assess 
endothelial function (Chowienczyk et al., 1999). Another form of stimulation used to 
record the digital volume changes is reactive hyperaemia, which has been shown to 
correlate with the brachial artery FMD measurements (Kuvin et al., 2003). 
 
1.5.2 Circulating biomarkers of endothelial function 
 
A number of circulating biomarkers have also been studied, as they were shown to 
be associated with endothelial dysfunction in human. These include the direct products of 
the endothelium as well as markers of endothelial damage and repair. Their levels in the 
circulation may serve as “surrogate markers” of endothelial function. At present, however, 
many of these circulating biomarker levels are still expensive and difficult to measure. 
 
Nitric oxide is a labile substance and thus not a good candidate to measure. Its 
generation by the endothelium on the other hand, may be reflected by the circulating levels 
of its metabolites, nitrite and nitrosylated proteins (Rassaf et al., 2004). However, these are 
technically difficult to measure and furthermore may be confounded by other sources of 
NO including dietary sources (Wang et al., 1997). Asymmetric dimethylarginine which has 
been implicated in the pathophysiology of endothelial dysfunction is also a good candidate 
as a surrogate marker. As mentioned above, high levels of ADMA were found in patients 
with risk factors such as hypercholesterolaemia. At present, the assay is still expensive and 
not widely used. C-reactive protein (CRP), which is synthesised by the liver has been a 
known marker of inflammatory response. In human plasma, it can be measured by high-
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sensitivity (hs) assays. Serum CRP levels has been shown to be inversely correlated with 
forearm blood flow response in patients with coronary artery disease (Fichtlscherer et al., 
2000). Endothelial vasodilator responses also improved when hs-CRP levels normalised. 
Thus, hs-CRP may serve as an indirect marker of endothelial dysfunction. Von Willebrand 
factor (vWF) is a high molecular weight glycoprotein synthesized mainly by the 
endothelium. In the coagulation cascade, it acts as a cofactor in platelet aggregation and 
adhesion. Elevated levels of vWF have been associated with risk factors of atherosclerosis. 
Furthermore, the levels were also shown to be reduced with treatment (Seljeflot et al., 
1999). Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI-1) are 
also endothelium-derived regulators of fibrinolysis. Their levels have been associated with 
increased cardiovascular risk and may be predictive of adverse events (Juhan-Vague et al., 
1996). However, they may not be specific for endothelial dysfunction, as these factors are 
not exclusively produced by the endothelium. Moreover, their levels may also be 
influenced by other pathological states (Farouque and Meredith, 2001).  
 
Cellular adhesion molecules (CAMs) mediate migration and adhesion of leukocytes 
to the endothelial wall. These include E-selectin, P-selectin, vascular adhesion molecule-1 
(VCAM-1) and intercellular adhesion molecule-1 (ICAM-1). The soluble forms of these 
molecules can be quantified by the enzyme immunological assays (Gearing and Newman, 
1993). Elevated levels of soluble CAMs have been shown to be associated with 
cardiovascular risk in healthy subjects as well as predictors of adverse outcome in patients 
with established coronary disease (Blankenberg et al., 2001, Hwang et al., 1997). 
Circulating endothelial cells that detach into the circulation following endothelial activation 
can be measured by flow cytometry or fluorescent microscopy (Goon et al., 2005). 
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Elevated levels of endothelial cells in the peripheral circulation have been detected in 
patients with atherosclerosis and vascular inflammation (Diamant et al., 2004). Likewise, 
circulating EPC may also be detected by flow cytometry. This is in support of the 
hypothesis that EPC deficiency may play a role in the pathogenesis of endothelial function 
as mentioned above. However, the measurements of both circulating cells are still under 
extensive studies and have not been applied clinically.  
 
Even though the measurements of circulating biomarkers may seem to be good 
surrogate markers for endothelial dysfunction, in reality many further studies are needed 
before it can be fully and widely applied. The measurements of circulating biomarkers are 
currently only used in a research setting and have not been applied clinically. This is owing 
to the fact that they are non-specific, technically difficult to perform as well as expensive. 
 
1.6 Pulse wave analysis 
 
Pulse wave analysis (PWA) is a non-invasive method to assess central pressure and 
arterial stiffness (Siebenhofer et al., 1999, Liang et al., 1998, Wilkinson et al., 1998). Using 
the SphygmoCor system developed by O’Rourke et al. (1993), it involves the principle of 
applanation tonometry whereby a maximal pulsation of superficial artery (e.g. radial, 
carotid or femoral) is minimally flattened or applanated by a tonometer. Minimal flattening 
of the artery allows accurate recording of the pressure waveform. The piezoelectrical 
crystal within the tonometer records the changes in the electrical resistance of the pressure 
waveform obtained. An approximately 10-second recording of the peripheral artery 
waveform generates a corresponding central aortic waveform by using a validated transfer 
 20
function (Pauca et al., 2001, Chen et al., 1997). SphygmoCor system generates 2 indices of 
arterial stiffness namely augmentation index (AIx) and pulse wave velocity (PWV) 
(O'Rourke et al., 2001, Wilkinson et al., 1998).  
 
The measurement of AIx is defined as the difference between the second and first 
systolic peaks, expressed as percentage of pulse pressure (%). This is based on the principle 
that large arteries are compliant structures, thus absorb some of the pressure which result 
from the ventricular ejection of blood into the aorta. These pressure waves which are 
reflected back from the periphery form the second peak, whereas the forward waves from 
the ventricular ejection form the fist peak. Normally the reflected waves arrive in the 
central arteries after aortic valve closure. However, in a stiff vessel, the velocity and 
amplitude of the reflected waves increase, resulting in an earlier arrival which then 
augments the central systolic pressure. This augmentation is then calculated as the index of 
arterial stiffness (O'Rourke et al., 2001, Wilkinson et al., 1998). The utilisation of AIx as an 
index to measure arterial stiffness has been well established, for instance in the Conduit 
Artery Function Evaluation Study (CAFÉ) (Williams et al., 2006) and Preterax in 
Regression of Arterial Stiffness in a controlled Double Blind Study (REASON) (Asmar et 
al., 2001).  
 
The changes in AIx after the administration of an endothelium dependent 
vasodilator have been tested as a tool to measure endothelial function (Hayward et al., 
2002, Wilkinson et al., 2002a). The details of this method have been explained above. It 
was based on the fact that systemic administration of β2-agonist changed the arterial 
pressure waveform. More importantly, the changes induced by β2-agonist could be blunted 
 21
by L-NMMA, and thus this pulse wave methodology could be applied as a method to assess 
endothelial function. In this thesis, assessment of endothelial function was based on this 
methodology whereby systemic administration of β2-receptor agonist was used as an 
endothelium dependent vasodilator and sublingual GTN, an endothelium-independent 
vasodilator acts as a control.  
 
Another index of arterial stiffness generated by the SphygmoCor system is pulse 
wave velocity (PWV). It involves a measurement of the time taken for the arterial pulse to 
propagate between 2 points in the arterial tree (Stewart et al., 2003, Wilkinson et al., 1998). 
Wave transit time between the 2 points is recorded using the R wave of a simultaneously 
recorded echocardiogram (ECG) as the referenced time. When recorded between carotid 
and femoral pulsations sequentially, as most commonly done, it then acts as a marker for 
aortic stiffness. The velocity is expressed as meter per second (m/s). Carotid-femoral PWV 
is also a well established method to assess arterial stiffness. In the currently ongoing 
clinical trial “Ongoing Telmisartan Alone and in Combination with Ramipril Global 
Endpoint Trial” and “Telmisartan Randomised AssessmeNT Risk Management Study in 
aCE iNtolerant” (ONTARGET/TRANSCEND), this parameter was used to measure arterial 
stiffness (Teo et al., 2004). In fact, compared to other parameters provided by PWA, it has 
been argued that PWV is a stronger predictor of cardiovascular and all cause mortality 
especially in high risk patients (Baulmann et al., 2006, London and Cohn, 2002, Laurent et 
al., 2001). Even though PWV is not routinely used as a tool to assess endothelial function, 
this simple measurement was incorporated into this thesis to observe the changes in PWV 
in response to GTN and salbutamol. Thus it would be interesting to test if the changes in 
PWV after the pharmacological challenges could also be used as a tool to assess endothelial 
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function. To date, there are still no published work where both entities; AIx and PWV are 
studied together in the assessment of endothelial function. This thesis presents the first 
study looking at the changes with both GTN and salbutamol using both parameters of 
arterial stiffness. 
 
1.7 Beta-2 adrenergic receptors 
 
Beta-2 adrenergic receptors or adrenoceptors (β2AR) are the target receptors for 
endogenous catecholamines i.e. adrenaline and noradrenaline and thus play an important 
role in the regulation of the sympathetic nervous system in the body. They are expressed 
mostly in the bronchial and vascular smooth muscle cells, being responsible to mediate 
bronchodilation and vasodilatation respectively (Guimaraes and Moura, 2001). They are 
also found in the heart and mediate positive inotropic and chronotropic effect, but less so 
than that of β1AR. To a lesser extent, they are also found on glands, adipocytes, leukocytes, 
hepatocytes, gastrointestinal smooth muscle and myometrial membrane of uterus (Hoffman 
and Taylor, 2001).  
 
Beta-2 adrenergic receptors are 7-membrane spanning G-protein-coupled receptors, 
and were first cloned in 1987 (Kobilka et al., 1987). In the vascular smooth muscle cells, 
agonist stimulation causes it to couple with stimulatory G protein (Gs). This stimulates 
adenylyl cyclase which results in an increase in the second messenger cyclic AMP (cAMP). 
The increase in cAMP levels activates protein kinase A. This in turn phosphorylates myosin 
light-chain kinase within the smooth muscle resulting in relaxation and vasodilatation 
(Lefkowitz et al., 2002, Murray, 1990). Other than this classical pathway, β2AR stimulation 
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also leads to NO generation by the vascular endothelium. Several possible pathways have 
been proposed to be responsible for the β2AR-mediated NO generation. In vitro studies 
have shown that the elevation of cAMP and protein kinase A activation also leads to 
stimulation of endothelium nitric oxide synthase (eNOS) (Yao et al., 2003, Ferro et al., 
1999). As has been explained previously, this enzyme leads to an increase in the production 
of nitric oxide (NO) by the endothelium. Nitric oxide, being a potent vasodilator acts by 
stimulating guanylyl cyclase; resulting in an increase in cGMP. Cyclic GMP induces 
smooth muscle relaxation and hence vasodilatation. In addition to the main pathways 
above, another possible pathway proposed for the β2AR-mediated NO generation is via 
inhibitory G protein (Gi) coupling. It has been shown in vitro that following agonist 
stimulation, β2AR also couples with Gi protein. This in turn stimulates phosphatidylinositol 
3’ kinase which then leads to stimulation of eNOS (Dimmeler et al., 1999, Fulton et al., 
1999).  
  
Based on its function in mediating the effects of catecholamines, β2AR become the 
target receptors for adrenergic drug treatments like β2 agonists and antagonists. Beta-2 
agonist for example salbutamol, is widely used as a bronchodilator in the treatment of 
asthma whereas non-selective β antagonists or β blockers are used in the treatment of 
hypertension and several other conditions. 
 
1.8 Beta-2 adrenergic receptor polymorphisms 
 
Polymorphism is defined as variability in deoxyribonucleic acid (DNA) sequence 
that occurs with an allele frequency of more than one percent (> 1%) in the population. 
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